Detection of growth hormone abuse in sport

Growth Hormone and IGF Research

Volumn 17, Issue 3, 2007, Pages 220-226

  Powrie, J K ^a   Bassett, E E ^b   Rosen, T ^e   Jorgensen J O ^d   Napoli, R ^c   Sacca, L ^c   Christiansen, J S ^d   Bengtsson, B A ^e   Sonksen P H ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF KENT   (United Kingdom)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Doping in sport; Growth hormone; Insulin like growth factor I; Procollagen type III

Indexed keywords

BIOCHEMICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; GROWTH HORMONE; HUMAN GROWTH HORMONE; OSTEOCALCIN; PLACEBO; PROCOLLAGEN TYPE 1 CARBOXYPROPEPTIDE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PROTEIN PRECURSOR; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; COMPETITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPING; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG SENSITIVITY; FEMALE; GENDER BIAS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SPORTS MEDICINE;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; DOPING IN SPORTS; DOUBLE-BLIND METHOD; FEMALE; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; PEPTIDE FRAGMENTS; PLACEBOS; PROCOLLAGEN; SUBSTANCE-RELATED DISORDERS;

EID: 34250169050     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2007.01.011     Document Type: Article

References (20)

1. Cuneo R., Salomon F., Wiles C., Hesp R., and Sonksen P.H. Growth hormone treatment in growth hormone-deficient adults. 11. Effects on exercise performance. J. Appl. Physiol. 70 2 (1991) 695-700
2. Cuneo R., Salomon F., Wiles C., Hesp R., and Sonksen P.H. Growth hormone treatment in growth hormone-deficient adults. 1. Effects on muscle mass and strength. J. Appl. Physiol. 70 2 (1991) 688-694
3. Salomon F., Cuneo R.C., Hesp R., and Sonksen P.H. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N. Engl. J. Med. 321 (1989) 1797-1803
4. Jorgensen J.O.L., Pedersen S.A., Thuesen L., Jorgensen J., Ingemann-Hansen T., Skakkebaek N.E., et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1 (1989) 1221-1225
5. McGauley G.A., Cuneo R.C., Salomon F., and Sonksen P.H. Psychological well-being before and after growth hormone treatment in adults with growth hormone deficiency. Horm. Res. 33 Suppl. 4 (1990) 52-54
6. Sonksen P.H. Insulin, growth hormone and sport. J. Endocrinol. 170 1 (2001) 13-25
7. Rickert V.I., Pawlak C., Sheppard V., and Jay M.S. Human growth hormone: a new substance of abuse amongst adolescents?. Clin. Paediatr. 31 12 (1992) 723-726
8. Parisotto R., Gore C.J., Emslie K.R., Ashenden M.J., Brugnara C., Howe C., et al. A novel method utilising markers of altered erythropoiesis for the detection of recombinant human erythropoietin abuse in athletes. Hematologica 85 (2000) 564-572
9. Lasne J., and de Ceaurriz J. Recombinant erythropoietin in urine. Nature 405 (2000) 635
10. Jenkins P. Cancer in acromegaly. Trends Endocrin. Metab. 9 (1998) 360-366
11. Wu Z., Bidlingmaier M., Dall R., and Strasburger C. Detection of doping with human growth hormone. Lancet 353 (1999) 895
12. Longobardi S., Keay N., Ehrnborg C., Cittadini A., Rosen T., Dall R., et al. Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study. The GH-2000 Study Group. J. Clin. Endocrinol. Metab. 85 4 (2000) 1505-1512
13. Dall R., Longobardi S., Ehrnborg C., Keay N., Rosen T., Jorgensen J.O., et al. The effects of 4 weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. J. Clin. Endocrinol. Metab. 85 11 (2000) 4193-4200
14. Healy M.-L., Dall R., Gibney J., Bassett E., Ehrnborg C., Pentecost C., et al. Towards the development of a test for growth hormone abuse: A study of extreme physiological ranges of GH-dependent markers in 813 elite athletes in the post-competition setting. J. Clin. Endocrinol. Metab. 90 (2005) 641-649
15. Burman P., Johansson A.G., Siegbahn A., Vessby B., and Karlsson F.A. Growth hormone deficient men are more responsive to GH replacement than women. J. Clin. Endocrinol. Metab. 82 2 (1997) 550-555
16. Kurdy N.M., Bowles S., Marsh D.R., Davies A., and France M. Serology of collagen types I and III in normal healing of tibial shaft fractures. J. Orthop. Trauma 12 2 (1998) 122-126
17. Kniess A., Zeigler E., Kratzsch J., Thieme D., and Muller R.K. Potential parameters for the detection of hGH doping. Anal. Bioanal. Chem. 376 5 (2003) 696-700
18. Kicman A.T., Miell J.P., Teale J.D., Powrie J., Wood P.J., Laidler P., et al. Serum IGF-I and IGF binding proteins 2 and 3 as potential markers of doping with human GH. Clin. Endocrinol. 47 1 (1997) 43-50
19. Baumann G. Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr. Rev. 12 (1991) 424-449
20. Abramson F.P., Osborn B.L., and Teffera Y. Isotopic difference in human growth hormone preparations. Anal. Chem. 68 (1996) 1971-1972